NICE Increases Options For Hyperkalemia Patients In England
Vifor’s Veltassa & AstraZeneca’s Lokelma Get Green Light
Executive Summary
Patients with high levels of blood potassium in England have two more options for treating their condition after NICE reversed its earlier negative recommendations.
You may also be interested in...
Vifor Confident About Veltassa Despite AZ Rival
The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.
Potassium Lowering Therapies Hit NICE Hurdle In UK
AstraZeneca’s Lokelma and Vifor’s Veltassa will be subject to a final review by the England and Wales health technology appraisal body in December following draft guidance not recommending their use in the National Health Service to treat hyperkalemia.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.